Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

Completed · Phase 1

Conditions studied: Psoriasis

In brief

The general aim of the trial is to determine the safety, tolerability and pharmacologic profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously to patients with chronic plaque psoriasis

Key facts

Study ID

NCT00848055

Run by

Boehringer Ingelheim

People needed

40

Starts

2008-12-01

Last updated by the study team

2013-11-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with chronic plaque psoriasis covering at least 3% of body surface area. Female subjects must be postmenopausal or surgically sterilized.

You may not qualify if…

• Recent use of biologic agents, oral psoriasis medications or phototherapy

Where it is running

• 1240.1.05 Boehringer Ingelheim Investigational Site — Boise, Idaho, United States
• 1240.1.06 Boehringer Ingelheim Investigational Site — Evansville, Indiana, United States
• 1240.1.04 Boehringer Ingelheim Investigational Site — Baltimore, Maryland, United States
• 1240.1.02 Boehringer Ingelheim Investigational Site — Boston, Massachusetts, United States
• 1240.1.01 Boehringer Ingelheim Investigational Site — New York, New York, United States
• 1240.1.03 Boehringer Ingelheim Investigational Site — Dallas, Texas, United States
• 1240.1.7 Boehringer Ingelheim Investigational Site — Berlin, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.